Payment overview · 2025
General Payments
$1,253.91
65 reported records · 22 companies
Healthcare provider profile · identity verified
Renae Furar, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · AVONDALE, AZ · NPI 1093273682
Verified facts
What the public records show
CMS Open Payments records show Renae Furar, APRN received $1,253.91 in general payments during 2025 across 65 reported records.
Amgen Inc. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $186.49 | 14.9% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $184.78 | 14.7% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $124.66 | 9.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $120.07 | 9.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $101.33 | 8.1% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $65.10 | 5.2% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.18 | 4.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.97 | 3.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $37.36 | 3.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.08 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.77 | 2.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.71 | 2.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.10 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.85 | 2.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.15 | 2.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.52 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.19 | 1.6% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $19.27 | 1.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $17.78 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.65 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.39 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.51 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,253.91 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.65 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $119.77 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.81 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $101.33 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.02 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.90 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.90 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $65.89 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $65.10 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $59.18 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.76 | 3 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.56 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.17 | 2 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $29.94 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 231 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 179 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 30 |
| Losartan Potassium | Losartan Potassium | 149 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 139 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 46 |
| Lisinopril | Lisinopril | 130 | 54 |
| Tramadol Hcl | Tramadol Hcl | 108 | 35 |
| Trazodone Hcl | Trazodone Hcl | 105 | 35 |
| Gabapentin | Gabapentin | 104 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 26 |
| Metformin Hcl | Metformin Hcl | 81 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 27 |
| Potassium Chloride | Potassium Chloride | 64 | 22 |
| Prednisone | Prednisone | 64 | 39 |
| Furosemide | Furosemide | 62 | 19 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 18 |
| Pregabalin | Pregabalin | 49 | 14 |
| Mirtazapine | Mirtazapine | 46 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 16 |
| Ozempic | Semaglutide | 41 | 12 |
| Famotidine | Famotidine | 39 | 21 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 11 |
| Simvastatin | Simvastatin | 38 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 12 |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 16 |
| Omeprazole | Omeprazole | 36 | 17 |
| Sertraline Hcl | Sertraline Hcl | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 15 |
| Fentanyl | Fentanyl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 23 |
| Fluconazole | Fluconazole | 27 | 20 |
| Eliquis | Apixaban | 26 | 11 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nystatin | Nystatin | 22 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Cephalexin | Cephalexin | 18 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,253.91 · 65 records | Amgen Inc. | ABRYSVO, AIRSUPRA, BARRIGEL, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, General - Therapies, ID NOW INSTRUMENT, INSPIRE, INTELLIS ADAPTIVESTIM, JASCAYD, JOT DX, KISUNLA, KRYSTEXXA, Kerendia, Korlym, Leqembi, MINIMED 780G, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, UBRELVY, VRAYLAR, Veozah, Wegovy, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error